Radiation Protection Effects of Metformin in Prostate Cancer
Not Applicable
Recruiting
- Conditions
- Prostate cancer.Malignant neoplasm of prostate
- Registration Number
- IRCT20170307032933N3
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 60
Inclusion Criteria
Patients with localized prostate cancers that undergo definitive or postoperative external radiotherapy
Exclusion Criteria
Patients with metastatic prostate cancer
Patients previously treated with radiotherapy or chemotherapy
Patients with renal or liver dysfunction
Patients with severe respiratory diseases (such as obstructive pulmonary disorders or severe asthma)
Patients with hematological disorders (such as severe anemia or vitamin B12 deficiency)
Diabetic patients
Smoker patients
Metformin hypersensitivity
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Radiation protection effect. Timepoint: At 0, every two weeks during radiotherapy course and one month after the final session of radiotherapy. Method of measurement: Oxidative stress tests.
- Secondary Outcome Measures
Name Time Method rogenital complications. Timepoint: At 0, every two weeks during radiotherapy course and one month after the final session of radiotherapy. Method of measurement: Toxicity Criteria of the Radiation Therapy Oncology Group.